Neuroscience startup Alto Neuroscience files for NYSE IPO: No revenue yet, $25.09 million net loss in first nine months of 2023

Built upon over a decade of methodology and data accumulation, Alto Neuroscience’s AI platform can identify patients likely to respond to treatment and leverage biomarkers to accelerate drug development. Alto Neuroscience identifies biomarkers—and constructs its drug pipeline—in a similar manner, focusing closely on core domains of psychological function (cognition, emotion, and sleep) and their underlying brain circuits. By evaluating functional brain metrics such as electroencephalography (EEG), along with behavioral and computerized tests using wearable devices, the company stratifies patients and matches them with appropriate Alto-developed therapeutics. According to its IPO prospectus, Alto Neuroscience generated $210,000 in revenue in 2021, and reported zero revenue from 2022 through the present. Alto Neuroscience’s operating losses were $12.06 million and $29.19 million in 2021 and 2022, respectively; its net losses were $9.19 million and $27.71 million, respectively. In the first nine months of 2023, Alto Neuroscience incurred a net loss of $25.09 million, compared to a net loss of $20.06 million in the same period of the prior year. Cumulative funding exceeds $100 million Since its founding, Alto Neuroscience has raised over $100 million in financing. In January 2023, Alto Neuroscience announced a $25 million equity investment, bringing its Series B round total to $60 million. Alto has also entered into a $35 million credit facility with K2 HealthVentures, enabling access to additional capital and flexibility as it advances its clinical-stage pipeline. At the end of November 2023, Alto Neuroscience announced a $45 million Series C financing round, led by InVivium Capital, with new investors including Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments.

AI security demand translates into orders! Palo Alto Networks’ earnings exceed expectations; CEO declares trillion-dollar 'security debt' urgently needs repayment

Artificial intelligence is accelerating the automation of cyberattacks, prompting enterprises to reassess their security investments. Palo Alto Networks’ annual profit and quarterly revenue guidance both surpassed market expectations—indicating that AI-related defense demand has begun converting into tangible order momentum. Cybersecurity firm Palo Alto Networks released its fiscal year 2026 fourth-quarter and full-year results on Tuesday. Its full-year adjusted EPS guidance stands at $4.16–$4.19, above the analyst consensus estimate of $4.11. Meanwhile, its first-quarter revenue guidance ranges from $3.3 billion to $3.31 billion—also exceeding the analyst consensus expectation of $3.21 billion. Following the earnings release, Palo Alto Networks’ stock surged over 6% after hours but later reversed course, closing down approximately 2%. Year-to-date through Tuesday’s close, the stock has nearly doubled; since April 7, it has risen 113%. Earnings beat—but narrowing gross margin raises concerns Palo Alto Networks delivered solid overall performance in its fiscal Q4, with next-generation security annual recurring revenue also surpassing market expectations. However, its gross margin narrowed: Q4 consolidated gross margin declined to 74.8%, down from 75.8% for the full fiscal year. CFO Dipak Golechha attributed this decline to the company’s strategic shift toward a software-as-a-service (SaaS) model, noting that this transition will cause cloud-hosting costs to grow faster than total revenue during fiscal year 2027—a statement that may have contributed significantly to the post-earnings share price reversal. The company also announced on the same day the completion of its acquisition of Console, a firm specializing in helping enterprises build AI agents capable of automating internal IT tasks. Trillion-dollar 'cybersecurity debt' awaits repayment He cited Anthropic’s Mythos model—launched earlier this year—as an industry-wide inflection point in awareness.

Alto Ingredients (ALTO) to Post Earnings on Wednesday

Jul 29, 2026

Alto Ingredients Inc will release Q2 2026 earnings on August 5th after market close. Analysts forecast $0.08 EPS on $231.2 million revenue, building on a previous quarter beat.

MarketBeat

2026-05-06

Alto Ingredients (NASDAQ: ALTO) returns to profit with stronger Q1 2026 margins

2026-05-06

Alto Ingredients: Q1 Earnings Snapshot

2026-05-06

Alto Ingredients Inc. (ALTO) Stock Rises on Q1 2026 Earnings

2026-05-06

Alto Ingredients Profit Turnaround Reshapes Investment Case Amid Tax Credits

2026-05-07

Alto Ingredients, Inc. Reports First Quarter 2026 Results